Total Payments
$361,341
2024 Payments
$24,309
Companies
33
Transactions
382
Medicare Patients
928
Medicare Billing
$97,985
Payment Breakdown by Category
Other$257,842 (71.4%)
Consulting$62,417 (17.3%)
Travel$26,734 (7.4%)
Food & Beverage$7,486 (2.1%)
Research$6,352 (1.8%)
Education$510.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $255,342 | 85 | 70.7% |
| Consulting Fee | $62,417 | 22 | 17.3% |
| Travel and Lodging | $26,734 | 57 | 7.4% |
| Food and Beverage | $7,486 | 200 | 2.1% |
| Unspecified | $6,352 | 7 | 1.8% |
| Honoraria | $2,500 | 1 | 0.7% |
| Education | $510.40 | 10 | 0.1% |
Payments by Type
General
$354,989
375 transactions
Research
$6,352
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $171,352 | 104 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $38,825 | 39 | $0 (2024) |
| GENZYME CORPORATION | $31,095 | 33 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $30,994 | 19 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $28,503 | 23 | $0 (2023) |
| Genentech USA, Inc. | $22,995 | 38 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $17,019 | 20 | $0 (2018) |
| F. Hoffmann-La Roche AG | $5,395 | 6 | $0 (2023) |
| EMD Serono, Inc. | $3,527 | 23 | $0 (2023) |
| Greenwich Biosciences, Inc. | $3,424 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,309 | 14 | Biogen, Inc. ($15,000) |
| 2023 | $43,312 | 45 | Biogen, Inc. ($19,272) |
| 2022 | $61,603 | 82 | Biogen, Inc. ($36,554) |
| 2021 | $48,202 | 60 | Biogen, Inc. ($29,422) |
| 2020 | $32,209 | 30 | Biogen, Inc. ($22,405) |
| 2019 | $50,452 | 51 | Novartis Pharmaceuticals Corporation ($15,678) |
| 2018 | $58,488 | 62 | Biogen, Inc. ($23,413) |
| 2017 | $42,768 | 38 | GENZYME CORPORATION ($19,740) |
All Payment Transactions
382 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 11/14/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $503.96 | General |
| 10/02/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $31.23 | General |
| Category: Neurology | ||||||
| 07/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| 07/09/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,340.00 | General |
| 05/31/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $54.46 | General |
| Category: Neurology | ||||||
| 05/13/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| Category: Neurology | ||||||
| 05/02/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| Category: Neurology | ||||||
| 05/02/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Neurology | ||||||
| 04/10/2024 | Biogen, Inc. | TYSABRI (Biological) | Consulting Fee | Cash or cash equivalent | $343.00 | General |
| Category: Neurology | ||||||
| 04/10/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $171.00 | General |
| 03/28/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| Category: Neurology | ||||||
| 03/26/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $46.92 | General |
| Category: Neurology | ||||||
| 01/11/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: Immunology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | Enspryng (Biological) | — | In-kind items and services | $2,028.52 | Research |
| Study: Satralizumab Treatment in Adults With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Retrospective Case Series • Category: Immunology | ||||||
| 12/08/2023 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,415.00 | General |
| 11/15/2023 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $298.00 | General |
| 11/08/2023 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,839.00 | General |
| Category: Neurology | ||||||
| 11/02/2023 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,550.00 | General |
| 10/03/2023 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $345.00 | General |
| 09/30/2023 | EMD Serono, Inc. | — | Travel and Lodging | Cash or cash equivalent | $128.04 | General |
| 09/18/2023 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,839.00 | General |
| 08/23/2023 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,291.00 | General |
| 08/10/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $34.34 | General |
| Category: Immunology | ||||||
| 07/27/2023 | Alexion Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,680.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Satralizumab Treatment in Adults With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Retrospective Case Series | F. Hoffmann-La Roche AG | $2,514 | 2 |
| Satralizumab Treatment in Adult Patients With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder Switching From Other Therapies: A Case Series | F. Hoffmann-La Roche AG | $1,879 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $957.57 | 1 |
| Satralizumab Treatment in Adult Patients With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series | F. Hoffmann-La Roche AG | $914.18 | 1 |
| Satralizumab Treatment in Adult Patients With AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder Switching From Other Therapies: Case Series | F. Hoffmann-La Roche AG | $87.48 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 222 | 265 | $76,422 | $23,015 |
| 2022 | 8 | 262 | 373 | $90,107 | $30,810 |
| 2021 | 7 | 221 | 273 | $60,440 | $24,159 |
| 2020 | 8 | 223 | 273 | $55,024 | $20,002 |
Total Patients
928
Total Services
1,184
Medicare Billing
$97,985
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 52 | 63 | $23,184 | $6,919 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 52 | 58 | $14,326 | $4,613 | 32.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 61 | $11,773 | $3,525 | 29.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $10,672 | $3,116 | 29.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $9,858 | $2,985 | 30.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 14 | $4,074 | $1,238 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 15 | $2,535 | $619.01 | 24.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 48 | 123 | $20,214 | $6,511 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 68 | $15,151 | $5,701 | 37.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 48 | $15,508 | $5,682 | 36.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $13,812 | $4,626 | 33.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 32 | 32 | $9,898 | $3,140 | 31.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 32 | $7,659 | $2,377 | 31.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,249 | $1,516 | 35.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 24 | $3,616 | $1,257 | 34.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 64 | 77 | $15,400 | $6,676 | 43.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 40 | 46 | $12,420 | $5,502 | 44.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 28 | 28 | $10,920 | $4,216 | 38.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 37 | 66 | $9,900 | $3,406 | 34.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 23 | 23 | $6,325 | $2,350 | 37.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 15 | $3,225 | $1,042 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 18 | $2,250 | $966.95 | 43.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 28 | 35 | $9,450 | $3,479 | 36.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 43 | 48 | $9,600 | $3,296 | 34.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 41 | $8,815 | $3,249 | 36.9% |
About Dr. Mary Willis, M.D
Dr. Mary Willis, M.D is a Neurology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1710188248.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mary Willis, M.D has received a total of $361,341 in payments from pharmaceutical and medical device companies, with $24,309 received in 2024. These payments were reported across 382 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($255,342).
As a Medicare-enrolled provider, Willis has provided services to 928 Medicare beneficiaries, totaling 1,184 services with total Medicare billing of $97,985. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Cleveland, OH
- Active Since 05/31/2007
- Last Updated 06/11/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1710188248
Products in Payments
- TYSABRI (Biological) $53,101
- VUMERITY (Drug) $31,665
- AUBAGIO (Drug) $29,555
- ZEPOSIA (Drug) $20,950
- Dysport 300 U-1 (Drug) $12,967
- OCREVUS (Biological) $8,493
- Enspryng (Biological) $6,620
- Dysport (Drug) $4,037
- UPLIZNA (Drug) $2,648
- ULTOMIRIS (Biological) $1,775
- GILENYA (Drug) $1,467
- BOTOX (Biological) $164.19
- KESIMPTA (Drug) $139.27
- Mavenclad (Drug) $117.59
- NUPLAZID (Drug) $104.14
- TECFIDERA (Drug) $99.13
- LEMTRADA (Drug) $96.80
- Ocrevus (Biological) $87.40
- Briviact (Drug) $71.33
- BRIUMVI (Drug) $52.70
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Cleveland
Imad Najm, Md, MD
Neurology — Payments: $428,375
Neurology $428,375
Dr. Robert Bermel, M.d, M.D
Neurology — Payments: $427,113
Neurology $427,113
Robert Fox, Md, MD
Neurology — Payments: $403,845
Neurology $403,845
Benjamin Walter, Md, MD
Neurology — Payments: $384,235
Neurology $384,235
Mary Rensel, Md, MD
Neurology — Payments: $288,222
Neurology $288,222
Dr. Eric Baron, D.o,, D.O,
Neurology — Payments: $251,414
Neurology $251,414